| Nov 11 |
ESSA Pharma And 2 Other US Penny Stocks To Watch
|
| Nov 4 |
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials
|
| Nov 1 |
Sector Update: Health Care Stocks Rise Late Afternoon
|
| Nov 1 |
Top Midday Decliners
|
| Nov 1 |
Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy
|
| Nov 1 |
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
|
| Nov 1 |
ESSA Pharma tanks after terminating trial for its prostate cancer treatment
|
| Nov 1 |
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment
|
| Nov 1 |
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
|
| Oct 28 |
ESSA Pharma Insiders Placed Bullish Bets Worth US$709.0k
|
